CTMXCytomX Therapeutics, Inc.
$2.19-48% 1Y
$2.19
$2.1252 weeks$6.75
Price
-48%1YEnd-of-day closes, not the intraday tick.
P/En/a
Market value$476.3M
1 year-48%
5 years-63%
Charts
As reported to the SEC, without any scoring.
CytomX Therapeutics, Inc. (CTMX) reported revenue of $1.7M in Q3 2026 (quarter ended Sep 30, 2026), down 72% from the same quarter a year earlier. That came with net loss of $20M. For the full year FY2025, revenue was $76M (−45% year on year) with a net loss of $17M. The next results filing is expected around Feb 4, 2027, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Nov 5, 2026CytomX Therapeutics Announces Q3 2026 Financial Results and Provides.Earnings release · press release
- Aug 6, 2026CytomX Therapeutics Announces Q2 2026 Financial Results and Provides.Earnings release · press release
- Jul 27, 2026On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director, with an initial term expiring at the Company’s 2029 annual meeting of stockholders.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry